Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

Christopher R. Behrens, Edward H. Ha, Lawrence L. Chinn, Simeon Bowers, Gary Probst, Maureen Fitch-Bruhns, Jorge Monteon, Amanda Valdiosera, Abel Bermudez, Sindy Liao-Chan, Tiffany Wong, Jonathan Melnick, Jan Willem Theunissen, Mark Flory, Derrick Houser, Kristy Venstrom, Zoia Levashova, Paul Sauer, Thi Sau Migone, Edward H. Van Der Horst & 2 others Randall L. Halcomb, David Y. Jackson

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal properties of heterogeneous ADCs have led to new site-specific conjugation methods for improving ADC homogeneity. Most site-specific methods require extensive antibody engineering to identify optimal conjugation sites and introduce unique functional groups for conjugation with appropriately modified linkers. Alternative nonrecombinant methods have emerged in which bifunctional linkers are utilized to cross-link antibody interchain cysteines and afford ADCs containing four drugs/antibody. Although these methods have been shown to improve ADC homogeneity and stability in vitro, their effect on the pharmacological properties of ADCs in vivo is unknown. In order to determine the relative impact of interchain cysteine cross-linking on the therapeutic window and other properties of ADCs in vivo, we synthesized a derivative of the known ADC payload, MC-MMAF, that contains a bifunctional dibromomaleimide (DBM) linker instead of a conventional maleimide (MC) linker. The DBM-MMAF derivative was conjugated to trastuzumab and a novel anti-CD98 antibody to afford ADCs containing predominantly four drugs/antibody. The pharmacological properties of the resulting cross-linked ADCs were compared with analogous heterogeneous ADCs derived from conventional linkers. The results demonstrate that DBM linkers can be applied directly to native antibodies, without antibody engineering, to yield highly homogeneous ADCs via cysteine cross-linking. The resulting ADCs demonstrate improved pharmacokinetics, superior efficacy, and reduced toxicity in vivo compared to analogous conventional heterogeneous ADCs.

Original languageEnglish (US)
Pages (from-to)3986-3998
Number of pages13
JournalMolecular Pharmaceutics
Volume12
Issue number11
DOIs
StatePublished - Nov 2 2015
Externally publishedYes

Fingerprint

Cysteine
Pharmacology
Antibodies
Pharmaceutical Preparations

Keywords

  • ADC
  • antibody-drug conjugate
  • auristatin
  • bifunctional
  • CD98
  • conjugation
  • cysteine
  • DAR
  • dibromomaleimide
  • disulfide
  • Her2
  • hinge
  • homogeneous
  • interchain
  • linker
  • maleimide
  • MMAF
  • site-specific
  • trastuzumab

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. / Behrens, Christopher R.; Ha, Edward H.; Chinn, Lawrence L.; Bowers, Simeon; Probst, Gary; Fitch-Bruhns, Maureen; Monteon, Jorge; Valdiosera, Amanda; Bermudez, Abel; Liao-Chan, Sindy; Wong, Tiffany; Melnick, Jonathan; Theunissen, Jan Willem; Flory, Mark; Houser, Derrick; Venstrom, Kristy; Levashova, Zoia; Sauer, Paul; Migone, Thi Sau; Van Der Horst, Edward H.; Halcomb, Randall L.; Jackson, David Y.

In: Molecular Pharmaceutics, Vol. 12, No. 11, 02.11.2015, p. 3986-3998.

Research output: Contribution to journalArticle

Behrens, CR, Ha, EH, Chinn, LL, Bowers, S, Probst, G, Fitch-Bruhns, M, Monteon, J, Valdiosera, A, Bermudez, A, Liao-Chan, S, Wong, T, Melnick, J, Theunissen, JW, Flory, M, Houser, D, Venstrom, K, Levashova, Z, Sauer, P, Migone, TS, Van Der Horst, EH, Halcomb, RL & Jackson, DY 2015, 'Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs', Molecular Pharmaceutics, vol. 12, no. 11, pp. 3986-3998. https://doi.org/10.1021/acs.molpharmaceut.5b00432
Behrens, Christopher R. ; Ha, Edward H. ; Chinn, Lawrence L. ; Bowers, Simeon ; Probst, Gary ; Fitch-Bruhns, Maureen ; Monteon, Jorge ; Valdiosera, Amanda ; Bermudez, Abel ; Liao-Chan, Sindy ; Wong, Tiffany ; Melnick, Jonathan ; Theunissen, Jan Willem ; Flory, Mark ; Houser, Derrick ; Venstrom, Kristy ; Levashova, Zoia ; Sauer, Paul ; Migone, Thi Sau ; Van Der Horst, Edward H. ; Halcomb, Randall L. ; Jackson, David Y. / Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs. In: Molecular Pharmaceutics. 2015 ; Vol. 12, No. 11. pp. 3986-3998.
@article{4adec5ce9fb542df92425924a8d02952,
title = "Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs",
abstract = "Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal properties of heterogeneous ADCs have led to new site-specific conjugation methods for improving ADC homogeneity. Most site-specific methods require extensive antibody engineering to identify optimal conjugation sites and introduce unique functional groups for conjugation with appropriately modified linkers. Alternative nonrecombinant methods have emerged in which bifunctional linkers are utilized to cross-link antibody interchain cysteines and afford ADCs containing four drugs/antibody. Although these methods have been shown to improve ADC homogeneity and stability in vitro, their effect on the pharmacological properties of ADCs in vivo is unknown. In order to determine the relative impact of interchain cysteine cross-linking on the therapeutic window and other properties of ADCs in vivo, we synthesized a derivative of the known ADC payload, MC-MMAF, that contains a bifunctional dibromomaleimide (DBM) linker instead of a conventional maleimide (MC) linker. The DBM-MMAF derivative was conjugated to trastuzumab and a novel anti-CD98 antibody to afford ADCs containing predominantly four drugs/antibody. The pharmacological properties of the resulting cross-linked ADCs were compared with analogous heterogeneous ADCs derived from conventional linkers. The results demonstrate that DBM linkers can be applied directly to native antibodies, without antibody engineering, to yield highly homogeneous ADCs via cysteine cross-linking. The resulting ADCs demonstrate improved pharmacokinetics, superior efficacy, and reduced toxicity in vivo compared to analogous conventional heterogeneous ADCs.",
keywords = "ADC, antibody-drug conjugate, auristatin, bifunctional, CD98, conjugation, cysteine, DAR, dibromomaleimide, disulfide, Her2, hinge, homogeneous, interchain, linker, maleimide, MMAF, site-specific, trastuzumab",
author = "Behrens, {Christopher R.} and Ha, {Edward H.} and Chinn, {Lawrence L.} and Simeon Bowers and Gary Probst and Maureen Fitch-Bruhns and Jorge Monteon and Amanda Valdiosera and Abel Bermudez and Sindy Liao-Chan and Tiffany Wong and Jonathan Melnick and Theunissen, {Jan Willem} and Mark Flory and Derrick Houser and Kristy Venstrom and Zoia Levashova and Paul Sauer and Migone, {Thi Sau} and {Van Der Horst}, {Edward H.} and Halcomb, {Randall L.} and Jackson, {David Y.}",
year = "2015",
month = "11",
day = "2",
doi = "10.1021/acs.molpharmaceut.5b00432",
language = "English (US)",
volume = "12",
pages = "3986--3998",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "11",

}

TY - JOUR

T1 - Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs

AU - Behrens, Christopher R.

AU - Ha, Edward H.

AU - Chinn, Lawrence L.

AU - Bowers, Simeon

AU - Probst, Gary

AU - Fitch-Bruhns, Maureen

AU - Monteon, Jorge

AU - Valdiosera, Amanda

AU - Bermudez, Abel

AU - Liao-Chan, Sindy

AU - Wong, Tiffany

AU - Melnick, Jonathan

AU - Theunissen, Jan Willem

AU - Flory, Mark

AU - Houser, Derrick

AU - Venstrom, Kristy

AU - Levashova, Zoia

AU - Sauer, Paul

AU - Migone, Thi Sau

AU - Van Der Horst, Edward H.

AU - Halcomb, Randall L.

AU - Jackson, David Y.

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal properties of heterogeneous ADCs have led to new site-specific conjugation methods for improving ADC homogeneity. Most site-specific methods require extensive antibody engineering to identify optimal conjugation sites and introduce unique functional groups for conjugation with appropriately modified linkers. Alternative nonrecombinant methods have emerged in which bifunctional linkers are utilized to cross-link antibody interchain cysteines and afford ADCs containing four drugs/antibody. Although these methods have been shown to improve ADC homogeneity and stability in vitro, their effect on the pharmacological properties of ADCs in vivo is unknown. In order to determine the relative impact of interchain cysteine cross-linking on the therapeutic window and other properties of ADCs in vivo, we synthesized a derivative of the known ADC payload, MC-MMAF, that contains a bifunctional dibromomaleimide (DBM) linker instead of a conventional maleimide (MC) linker. The DBM-MMAF derivative was conjugated to trastuzumab and a novel anti-CD98 antibody to afford ADCs containing predominantly four drugs/antibody. The pharmacological properties of the resulting cross-linked ADCs were compared with analogous heterogeneous ADCs derived from conventional linkers. The results demonstrate that DBM linkers can be applied directly to native antibodies, without antibody engineering, to yield highly homogeneous ADCs via cysteine cross-linking. The resulting ADCs demonstrate improved pharmacokinetics, superior efficacy, and reduced toxicity in vivo compared to analogous conventional heterogeneous ADCs.

AB - Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal properties of heterogeneous ADCs have led to new site-specific conjugation methods for improving ADC homogeneity. Most site-specific methods require extensive antibody engineering to identify optimal conjugation sites and introduce unique functional groups for conjugation with appropriately modified linkers. Alternative nonrecombinant methods have emerged in which bifunctional linkers are utilized to cross-link antibody interchain cysteines and afford ADCs containing four drugs/antibody. Although these methods have been shown to improve ADC homogeneity and stability in vitro, their effect on the pharmacological properties of ADCs in vivo is unknown. In order to determine the relative impact of interchain cysteine cross-linking on the therapeutic window and other properties of ADCs in vivo, we synthesized a derivative of the known ADC payload, MC-MMAF, that contains a bifunctional dibromomaleimide (DBM) linker instead of a conventional maleimide (MC) linker. The DBM-MMAF derivative was conjugated to trastuzumab and a novel anti-CD98 antibody to afford ADCs containing predominantly four drugs/antibody. The pharmacological properties of the resulting cross-linked ADCs were compared with analogous heterogeneous ADCs derived from conventional linkers. The results demonstrate that DBM linkers can be applied directly to native antibodies, without antibody engineering, to yield highly homogeneous ADCs via cysteine cross-linking. The resulting ADCs demonstrate improved pharmacokinetics, superior efficacy, and reduced toxicity in vivo compared to analogous conventional heterogeneous ADCs.

KW - ADC

KW - antibody-drug conjugate

KW - auristatin

KW - bifunctional

KW - CD98

KW - conjugation

KW - cysteine

KW - DAR

KW - dibromomaleimide

KW - disulfide

KW - Her2

KW - hinge

KW - homogeneous

KW - interchain

KW - linker

KW - maleimide

KW - MMAF

KW - site-specific

KW - trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=84946567523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946567523&partnerID=8YFLogxK

U2 - 10.1021/acs.molpharmaceut.5b00432

DO - 10.1021/acs.molpharmaceut.5b00432

M3 - Article

VL - 12

SP - 3986

EP - 3998

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 11

ER -